Orion Portfolio Solutions LLC Decreases Stock Holdings in argenx SE (NASDAQ:ARGX)

Orion Portfolio Solutions LLC lessened its holdings in argenx SE (NASDAQ:ARGX) by 5.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,298 shares of the company’s stock after selling 502 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in argenx were worth $5,103,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Whipplewood Advisors LLC purchased a new position in shares of argenx in the 4th quarter valued at about $37,000. Global Retirement Partners LLC raised its holdings in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after buying an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock valued at $46,000 after buying an additional 33 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after buying an additional 21 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Down 0.7 %

Shares of ARGX opened at $589.15 on Friday. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21. The company has a 50-day simple moving average of $628.26 and a 200-day simple moving average of $601.66. The company has a market capitalization of $35.80 billion, a PE ratio of -669.49 and a beta of 0.59.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, research analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ARGX shares. HC Wainwright upped their price objective on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Citigroup restated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. William Blair reiterated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Oppenheimer raised their target price on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company upped their price target on shares of argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and an average price target of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.